PubMed Health⌕ Search

Biomedical subjects

S C Arya

Publications and source records attributed to S C Arya.

At least 181 records · Page 10Linked to original sources
PubMed1989

Glutaraldehyde in whole-cell Bordetella pertussis vaccine.

Treatment of the whole-cell bacterial suspensions of Bordetella pertussis with 0.05% glutaraldehyde at room temperature for 10 min kills the bacteria and, except for some histamine sensitising activity, almost detoxifies the pertussis toxin. The glutaraldehyde-vaccine is of good potency with a meritorious performance in tests for abnormal toxicity in mice, the leucocytosis-promoting-factor and the mouse weight gain. Using glutaraldehyde for the inactivation of whole-cell pertussis vaccine on a commercial scale must await extensive clinical trials with vaccine lots with a good record of safety and potency in animal tests.

Aldehydes↗
PubMed1988

Enhancement of field stability and utility of future biologicals through prior accelerated degradation testing.

The scepticism about the future utility of newer biologicals towards reducing disease morbidity or mortality at the public health or application level can be regarded as appropriate. The financial or research inputs into producing anti-idiotypic, subunit, cloned or genetically engineered products may not be transcribed to the field level due to political or economic impediments and the putative breakdown of any specific activity at the application level, as with the conventional immunobiologicals, may also negate the utility of the newer products. Such an eventuality should be overcome by planning, during the pre-licensure phase, appropriate accelerated degradation tests on newer biologicals.

DNA, Recombinant↗
PubMed1988

Testing for AIDS on samples of dried blood prepared on filter papers.

A substantial rise in the number of AIDS cases has been observed during the past year in many African countries, and HIV-2 indigenous transmission and increased disease have since gained importance in Senegal. Both for HIV-1 and HIV-2 diagnosis, ELISA positivity is followed by a Western blot test for specific antibodies. The serum samples are stored at sub-zero temperatures both during shipment and storage while awaiting serological testing. Attempts have been made to use dried blood on filter papers for AIDS diagnosis, in 35 samples from Africa and 10 from USA, along with corresponding serum samples. The concordance has been good with an almost invariable ELISA confirmation on Western blot, no selective loss in any of the bands in Western blot and the Pearson coefficient value for ELISA testing on serum and dried blood lots of 0.85. Based on the data obtained during the intentional exposure of blood-impregnated filter papers, from nine HIV-positive and one HIV-negative patient from the USA, to varying temperatures and humidity for different intervals, blood collection on filter paper would appear to have emerged as a satisfactory procedure for HIV seroepidemiological studies.

Blood Specimen Collection↗
PubMed1988

Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia.

Hepatitis B virus (HBV) has been hyperendemic in the Gizan area of Saudi Arabia, located 17 degrees N 43 degrees E, with 20% male and 9% female HBsAg carriers among the native population. Among HBsAg carriers, 8% have been positive for anti-delta antibody while intravenous drug abuse and alcohol have been unknown. Monthly hospitalisation of primary hepatocellular carcinoma (PHC) patients from a catchment population of 500,000 approximates 2-3. HBV markers were tested in 30 PHC cases and compared with 326 otherwise healthy natives. Both HBsAg and total HBV exposure were higher among PHC (p less than 0.001), with no difference between sexes. Anti-delta antibody was demonstrable in 5 of 30 HBsAg-positive PHC with similar distribution among PHC, healthy carriers and those with chronic hepatic disorders. Serum aliquots from 3 hitherto HBV-negative PHC cases are to be tested for HBV-DNA along with immunohistochemical staining on biopsy material. Pending reduction in PHC incidence decades later, subsequent to initiation of HBV immunization, regular examination of HBsAg carriers and established cirrhotics for alphafetoprotein level and ultrasonic hepatic lesions would constitute important interim measures both towards early detection of, and an effective chemotherapy/surgery for, hepatic malignancy.

Carcinoma, Hepatocellular↗
PubMed1986

A profile of primary hepatocellular carcinoma patients in the Gizan Area of Saudi Arabia.

Clinical, laboratory, and ultrasonographic features of 75 patients of primary hepatocellular carcinoma (PHC) living in the Gizan Area of Saudi Arabia and their follow-up, during a 2-year period, were characterized. Eighty-nine percent of the cases were defined histologically, whereas in the rest, ultrasonographic (US) evidence along with an alphafetoprotein (AFP) level exceeding 480 ng/ml were taken as the positive evidence for PHC. Eighty percent of the cases were male patients, with the peak incidence during the seventh decade. The most common clinical presentations were hepatic enlargement (91%), abdominal pain (76%), splenic enlargement (33%), and acites (33%), followed by bruit, fever, metastases, and varices. Alteration in a liver function test was manifest in 97% of the cases, AFP values greater than 480 ng/ml in 57%, and a hepatitis B virus surface antigen (HBsAg) positivity in 65% of the cases. There was no intersex variation in positivity for HBsAg, antibody to HBsAg (anti-HBs), antibody to hepatitis B virus core antigen (anti-HBc) among the 30 PHC cases studied. Positivity for HBsAg or the overall hepatitis B virus exposure in PHC cases was higher than the normal controls (P less than 0.001). In addition to histologic confirmation of PHC in 67 cases, there was histologic evidence of cirrhosis in 25%, or chronic active hepatitis in 19% of the cases. At the time of diagnosis, the average duration of the presenting illness was less than 2 months, while the mortality in the ensuing 2-month period was 73%. The average span of total illness in the vast majority of cases was 4 to 6 months. Two female patients (one with fibrolamellar carcinoma) however, survived for 2 years. Immunization against hepatitis B virus should be considered for all newborns in such hyperendemic communities. A continuous program should be started in such communities to screen and immunize all those yet unexposed to hepatitis B virus. The established HBsAg carriers should be periodically examined ultrasonographically along with an AFP estimation for initiating the chemotherapeutic and other measures against PHC in fairly early stages of malignancy.

Adult↗
PubMed1986

Viral hepatitis markers in patients on haemodialysis in a hyperendemic area.

Antibody profiles for cytomegalovirus (CMV), hepatitis A virus (HAV), hepatitis B virus (HBV) and the delta-agent were determined on 55 serum samples drawn from 55 Saudi patients on maintenance haemodialysis for periods ranging from 1.5 months to 2 years. The exposure rates for CMV, HAV, and HBV were 100%, 100%, and 72.7%, respectively. There was no intersex difference in positivity for HBV surface antigen (HBsAg), antibody to HBsAg (anti-HBs), antibody to HBV core antigen (anti-HBc); 15.4%, 65.4%, 3.8% in males and 6.9%, 55.2%, and 0% in females, respectively. Among six HBsAg carriers, one and three were positive for e antigen (HBeAg) and antibody to HBeAg (anti-HBe), respectively, with two negative for HBeAg and anti-HBe. The six carriers were also negative for anti-delta antibody. A comparison of the above antibody profile to the profile of voluntary blood donors and those seeking treatment for minor ailments in the local general hospital, obtained earlier using identical test procedures, revealed no difference for CMV and HAV exposure rate. The HBV exposure rate was higher in the haemodialysed patients (P less than 0.001). The epidemiological measures for preventing nosocomial viral hepatitis including immunisation of susceptibles, can be supplemented, among carriers, by interferon and acyclovir therapy for active viral replication. In HBV hyperendemic areas, haemodialysis patients exposed to HBV should be screened periodically for early signs of hepatocellular carcinoma.

Adolescent↗
PubMed1986

Frequencies of hepatitis B, delta and HTLV-III virus markers in Saudi Arabia.

Serum samples from 608 residents of Saudi Arabia were examined for the presence of hepatitis B, delta and HTLV-III virus markers. The HBsAg carrier rate was 17% and the prevalence of all hepatitis B virus markers was 55%. Males between 16 and 25 years had a significantly higher prevalence of all HBV markers (69%; 95% confidence limits: 49%-82%) compared to females in the same age group (34%; 95% confidence limits: 25%-45%). The prevalence of HBsAg was significantly higher among males aged 25-35 years (24%; 95% confidence limits: 19%-40%) compared to females in the same age group (9%; 95% confidence limits: 4%-18%). In addition, the HBsAg carrier rate for all males (23%) was significantly higher compared to females (11%) (p less than 0.001). HBeAg was found in 12% of 89 HBsAg-positive individuals, 48% were anti-HBe positive and 40% were negative for both markers. Hepatitis B virus DNA was found in 11 of 41 individuals tested. Five of these were HBeAg positive and four were anti-HBe positive. Anti-delta was found in three of 36 HBsAg positive serum samples (8%). Of 485 individuals tested for anti-HTLV-III, none were positive.

Adolescent↗